RxDoctor Payments Data

Hector Cabrera, MD

Family Medicine · New Orleans, LANPI 1922007012

Payments from drug & device makers

$687in general payments, 2019–2025

Across 25 payments — averaging $27.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$237
  • Organogenesis Inc.$105
  • Pfizer$91
  • UCB, Inc.$65
  • Lilly USA, LLC$51
  • Roche Diagnostics Corporation$31
  • plus $106 from 6 others

What the payments were for

  • Food & beverage$687100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$687 in reported general payments places this provider in the 50th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$153,508
Medicare patients
358
Services billed
2,155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban630$184,902
JanuviaSitagliptin Phosphate190$60,776
TrulicityDulaglutide39$46,579
EntrestoSacubitril/Valsartan72$26,084
Invega SustennaPaliperidone Palmitate11$25,664
XareltoRivaroxaban88$25,254
JardianceEmpagliflozin80$24,832
SantylCollagenase Clostridium Hist.54$22,704
MyrbetriqMirabegron98$22,341
BriviactBrivaracetam18$16,912
LinzessLinaclotide27$15,627
TradjentaLinagliptin54$14,062
NamzaricMemantine Hcl/Donepezil Hcl45$13,132
Atorvastatin Calcium1,034$13,039
Breo ElliptaFluticasone/Vilanterol28$12,082

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$91$184,902630 claims
AbbVieLinzess, Namzaric, Combigan, Lumigan, Restasis$16$48,994147 claims
Lilly USA, LLCTrulicity$51$46,57939 claims
NovartisEntresto$18$26,08472 claims
UCB, Inc.Briviact$65$16,91218 claims
AstraZenecaLokelma, Brilinta$237$11,84939 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →